118 results about "Ovarian tumor" patented technology

The present disclosure provides methods for classifying ovarian tumors into BRCA1-type, BRCA2-type or non-BRCA-type tumor types by measuring expression levels of a plurality of disclosed ovarian tumor markers. The markers disclosed herein are useful in the diagnosis, staging, detection, and / or treatment of ovarian cancer. Also provided are methods of selecting a treatment regimen by selecting the tumor type. Ovarian cancer-linked logarithmic expression ratios and kits for diagnosis, staging, and detection of ovarian cancer using are also provided.

The invention relates to methods of inhibiting proliferation or growth of tumor cells and / or inducing cell death in cancer cells. This invention relates to the use of antibodies, hybridomas and pharmaceutical compositions containing same, for inhibiting growth or proliferation and inducing death in epithelial, colon, lung, breast and ovarian tumor cells or other cells which express MUC1 proteins.

The present invention is related to methods of early diagnosis of ovarian cancer in a patient by determining serum levels of blood markers using a novel LabMAP™ technology (Luminex Corp., Austin, Tex.), which allows for simultaneous measurement of the blood markers in serum. The panel of blood markers offers extremely high predictive power for discrimination of ovarian cancer from both healthy control patients and from patients with benign pelvic / ovarian tumors. The methods of the present invention allow for rapid, early diagnosis of ovarian cancer with extremely high sensitivity and specificity to be clinically useful in disease diagnosis.

Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly ovarian cancer.

Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described are methods and compositions for treating folate receptor expressing epithelial tumors with a folate-vinca conjugate in combination with doxorubicin such as pegylated liposomal doxorubicin in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum sensitive ovarian tumors. Also described are methods of treating platinum-resistant ovarian cancer using a folate-targeted drug, in the absence or presence of selecting the patient by identifying functionally active folate receptors on the tumors of the patient.

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

In one aspect, the present invention provides a method for treating colon and / or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and / or ovarian tumor metastasis.

The invention provides an immunogenic composition comprising a GnRH multimer and an antigenic carrier, an immunogenic composition comprising a recombinant vector containing a nucleic acid molecule encoding a GnRH multimer and optionally an antigenic carrier, antibodies elicited by the immunogenic compositions, and methods of using the immunogenic compositions and antibodies for modifying sexual physiology and behavior, improving the organoleptic properties of meat, and treating androgen-dependent prostate tumors and GnRH-sensitive ovarian tumors.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

The invention provides a papillary serous miRNA signature and methods for determining the identity, origin, and stage, of concurrent endometrial and ovarian papillary serous tumors. Exemplary origins of concurrent endometrial and ovarian tumors include, but are not limited to, the uterus, ovary, fallopian tubes, and peritoneum.

The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents, which can be used to treat a mammalian host, usually a human, suspected of having cancer or tumor cells by administering the combination in a therapeutically- or synergistically-effective amount. The drug combinations cytotoxic to tumor cells comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and induces an increase in the phosphorylation of c-erbB-2 protein when placed in contact with the tumor cells. Alternatively, the drug combination cytotoxic to tumor cells may comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and causes down modulation or internalization of c-erbB-2 protein. The anti-neoplastic drug is preferably an alkylating agent, most preferably cisplatin. This combination is particularly effective for inhibiting the growth of breast and ovarian tumor cells. Methods for killing target tumor cells are contemplated by contacting the target cells with the novel drug combinations, methods for treating mammals by administering therapeutic amounts of the drug combinations are also contemplated.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of ovarian cancer cells and be used as a pharmaceutical composition to inhibit the ovarian tumor growth.

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.

The invention discloses an easy angle adjustment puncture device for ovarian tumors. The device comprises a cannula, a pipette, a puncture needle and two steel wires made from spring steel. The cannula is provided with a flared chuck, and the cannula, the pipette and the chuck are made from flexible materials. Inside the cannula, there are two channels extending in the axial direction of the cannula, wherein the two steel wires are respectively inserted. The front ends of the two steel wires are curved naturally, each wire is capable with rotatory operation in the channel. The puncture needle is arranged in the front end of the pipette, the pipette and the puncture needle, which are arranged in the cannula, are telescopically slideable upward along the cannula. The pipette and the puncture needle are respectively spaced from the inner wall of the cannula. The easy angle adjustment puncture device for ovarian tumors not only is capable with puncturing directly to the tumors excluding the tumor cells, but also is capable of holding the tumors, and is convenient of peeling and removing the tumors.

Compositions suitable for use as ovarian cancer and / or tumor adjuvants in the preparation of ovarian cancer vaccines, particularly those vaccines useful in the treatment of human ovarian cancer, are provided. The ovarian cancer adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), tracer, or other solid or semi-solid preparation. Also disclosed are ovarian tumor inhibiting compositions that include extracellular matrix tissue adjuvants.

The invention discloses a double sandwich immunoassay test kit labeled by HE4 quantum dots. The kit comprises HE4 protein standards, an ELISA plate coated with HE4 specific polyclonal antibodies, and CdTe quantum dots labeled monoclonal antibodies in specific binding with HE4 proteins. The invention further discloses an application of the kit in diagnosis of ovarian tumor. According to the invention, the test kit can directly determine test results through fluorescent ELISA, emitted fluorescence spectral peaks are narrow, autofluorescence is weak, and a sensitivity is high. The kit is high in fluorescence intensity and long in stable time, and can relatively effectively facilitate early detection and risk assessment of the ovarian tumor.

Cellular markers indicating a poor prognosis for ovarian cancer patients are disclosed. In particular, the invention relates to methods utilizing the frequency of a subset of cells in ovarian tumor tissue expressing vimentin, cMyc, or HE4, or any combination thereof, to predict an ovarian cancer patient will relapse.

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and / or cyclophosphamide).

A method and apparatus for predicting the estrus and the delivery date of a cow, a swine, a horse or the like and discovering diseases such as fasciolisasis and ovarian tumor thereof by analysis of values from an attachable vibrograph attached to a leg portion, a neck portion, a chin portion or the like of the cow, the swine, the horse or the like to obtain frequency value information, such as vibrations, walking states and non-walking states, due to the excitement of the cow, the swine, the horse or the like caused by estrus. The obtained frequency value information is transmitted, inputted and stored into a centralized computer such as a personal computer in units of hours, and the stored frequency value information is converted to the numerical values to be analyzed.

A method of detecting a granulosa-cell tumor is described herein. The method involves detecting a mutation in a sample derived from a subject, indicative of substitution of tryptophan in place of cysteine at amino acid position 134 of FOXL2 protein. The mutation may be detected as a DNA mutation 402C>G in the FOXL2 gene. Methods for screening for a granulosa-cell tumor from a blood-based assay are provided, as well as methods for making a determination that an ovarian tumor is not a granulosa-cell tumor. Kits for granulosa-cell tumors are described, and a method of treating a granulosa-cell tumor are also described.

The invention discloses a compound having the following general formula (I), wherein K is selected from a cycloalkane group shown in the following formula. The invention also discloses an indoleamine-2,3-dioxygenase inhibitor comprising the compound and an application of the compound in preparation of drugs for treating cancer. The compound of the invention can effectively inhibit cell proliferation, has a good therapeutic effect on various diseases such as cancer, has significant therapeutic effects on breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostatic cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, stage IV melanoma, glioma, glioblastoma, hepatocellular carcinoma, mastoid renal tumor, head and neck tumor, leukemia, lymphoma, myeloma, non-small cell lung cancer, and the like, and has very broad application prospects.

Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and / or cyclophosphamide).

A Chinese medicine for treating cancers and tumors is prepared from 17 Chinese-medicinal materials including ginseng, Chinese angelica root, Chuan-xiong rhizome, peach kernel, safflower, etc. Its advantages are sure curative effect and no toxic by-effect.

Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors.

In one aspect, the present invention provides a method for treating colon and / or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and / or ovarian tumor metastasis.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.